Literature DB >> 20624116

Novel therapies for pancreatic cancer: setbacks and progress.

Han Hsi Wong, Nicholas R Lemoine.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20624116      PMCID： PMC3748370          DOI： 10.2217/fon.10.70

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


× No keyword cloud information.
  34 in total

1.  Improved lentiviral transduction of human mesenchymal stem cells for therapeutic intervention in pancreatic cancer.

Authors:  G Kallifatidis; B M Beckermann; A Groth; M Schubert; A Apel; A Khamidjanov; E Ryschich; T Wenger; W Wagner; A Diehlmann; R Saffrich; U Krause; V Eckstein; J Mattern; M Chai; G Schütz; A D Ho; M M Gebhard; M W Büchler; H Friess; P Büchler; I Herr
Journal:  Cancer Gene Ther       Date:  2008-01-18       Impact factor: 5.987

2.  Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.

Authors:  Han Hsi Wong; Nicholas R Lemoine; Yaohe Wang
Journal:  Viruses       Date:  2010-01       Impact factor: 5.818

3.  Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer.

Authors:  Izuru Watanabe; Hideki Kasuya; Naohiro Nomura; Toshio Shikano; Takashi Shirota; Naohito Kanazumi; Shin Takeda; Shuji Nomoto; Hiroyuki Sugimoto; Akimasa Nakao
Journal:  Cancer Chemother Pharmacol       Date:  2007-08-29       Impact factor: 3.333

4.  Oncolytic virus therapy for pancreatic cancer using the adenovirus library displaying random peptides on the fiber knob.

Authors:  T Nishimoto; K Yoshida; Y Miura; A Kobayashi; H Hara; S Ohnami; K Kurisu; T Yoshida; K Aoki
Journal:  Gene Ther       Date:  2009-02-19       Impact factor: 5.250

5.  Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo.

Authors:  Stephan Leitner; Katrina Sweeney; Daniel Oberg; Derek Davies; Enrique Miranda; Nick R Lemoine; Gunnel Halldén
Journal:  Clin Cancer Res       Date:  2009-02-17       Impact factor: 12.531

6.  Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters.

Authors:  Sergia Bortolanza; Maria Bunuales; Itziar Otano; Gloria Gonzalez-Aseguinolaza; Carlos Ortiz-de-Solorzano; Daniel Perez; Jesus Prieto; Ruben Hernandez-Alcoceba
Journal:  Mol Ther       Date:  2009-02-17       Impact factor: 11.454

7.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

8.  Reexpression of human somatostatin receptor gene 2 gene mediated by oncolytic adenovirus increases antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand against pancreatic cancer.

Authors:  Zhenwei Zhang; Yangbin Huang; Kam Newman; Jinfa Gu; Xuemei Zhang; Hua Wu; Ming Zhao; Zhiqun Xianyu; Xinyuan Liu
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

Review 9.  Biological approaches to therapy of pancreatic cancer.

Authors:  Han Hsi Wong; Nicholas R Lemoine
Journal:  Pancreatology       Date:  2008-08-25       Impact factor: 3.996

10.  Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer.

Authors:  Sant P Chawla; Victoria S Chua; Lita Fernandez; Dorris Quon; William C Blackwelder; Erlinda M Gordon; Frederick L Hall
Journal:  Mol Ther       Date:  2009-10-13       Impact factor: 11.454
View more
  3 in total

1.  Repositioning of Old Drugs for Novel Cancer Therapies: Continuous Therapeutic Perfusion of Aspirin and Oseltamivir Phosphate with Gemcitabine Treatment Disables Tumor Progression, Chemoresistance, and Metastases.

Authors:  Bessi Qorri; Reza Bayat Mokhtari; William W Harless; Myron R Szewczuk
Journal:  Cancers (Basel)       Date:  2022-07-23       Impact factor: 6.575

2.  In vivo gene transfer targeting in pancreatic adenocarcinoma with cell surface antigens.

Authors:  Marie Lafitte; Benoit Rousseau; Isabelle Moranvillier; Miguel Taillepierre; Evelyne Peuchant; Véronique Guyonnet-Dupérat; Aurélie Bedel; Pierre Dubus; Hubert de Verneuil; François Moreau-Gaudry; Sandrine Dabernat
Journal:  Mol Cancer       Date:  2012-10-22       Impact factor: 27.401

Review 3.  Neuraminidase-1: a novel therapeutic target in multistage tumorigenesis.

Authors:  Fiona Haxho; Ronald J Neufeld; Myron R Szewczuk
Journal:  Oncotarget       Date:  2016-06-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.